We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prenatal Testing May Also Detect Some Maternal Cancers

By LabMedica International staff writers
Posted on 02 Aug 2015
Print article
A new bioinformatics study shows that prenatal genetic test results, such as revealed by noninvasive prenatal testing (NIPT) for fetal chromosome abnormalities, may also detect underlying conditions in the mother, including cancer.

Diagnosis of cancer during pregnancy is relatively uncommon (incidence about 1 in 1,000 women). A team of scientists and clinicians, led by Diana W. Bianchi, MD, of Tufts Medical Center (Boston, MA, USA) and the Reproductive and Genetic Health Expert Advisory Panel at Illumina (Redwood City, CA, USA), has reported results of their genome-wide analysis performed on available DNA sequencing data for a case series of 8 women with abnormal NIPT results. Analysis showed discordance with the fetal karyotype: while their fetuses had normal chromosomes, retrospective genomic analysis showed that the abnormal results were due to a variety of undiagnosed cancers in the mothers. The findings demonstrate that previously undetected maternal cancers may provide a biological explanation for some differences between results from prenatal diagnostic versus prenatal screening tests.

NIPT is a recent clinical advance that provides pregnant women with information about possible chromosomal abnormalities, such as Down syndrome, in their fetuses. The screening test, which can be offered as early as the 10th week of pregnancy, analyzes fragments of placental and maternal DNA that circulate in maternal plasma. In women with cancer, the plasma sample also contains cancer DNA.

“This study provides one explanation for when NIPT results are different from the fetal karyotype. It highlights the need to perform a diagnostic procedure to determine true fetal karyotype whenever NIPT suggests chromosomal abnormalities,” said Dr. Bianchi, expert on NIPT.

The 8 cases in this preliminary study of occult malignancy came from 125,426 samples submitted from asymptomatic pregnant women who underwent NIPT for fetal chromosomal abnormalities, of which 3757 cases were positive for one or more abnormalities in the number of chromosomes 13, 18, 21, X, or Y. The women’s physicians later reported 10 cases of cancer to the laboratory that originally conducted the NIPT, the study analyzed 8 of these in depth. All of the women had abnormal NIPT results, and most frequently, more than one chromosomal abnormality was detected, a very unusual result. Cancer was diagnosed during pregnancy or postpartum in these women at an average of 16 weeks following the initial NIPT. The clinical importance of these findings will require further research.

“NIPT results may lead to findings of an underlying maternal condition, which, in these cases, was due to cancer,” said Dr. Bianchi, “The take-home message is that women should be aware of this possibility when they seek testing. More research needs to be done to further study this occurrence to help guide physicians on how to counsel women and manage their follow-up care.”

The study, by Bianchi DW, et al, was published July 14, 2015, in the Journal of the American Medical Association (JAMA).

Related Links:

Tufts Medical Center
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.